WE TRACK THOUSANDS OF POLITICIANS EACH AND EVERY DAY!

Their Biographies, Issue Positions, Voting Records, Public Statements, Ratings and their Funders.

Letter to Barack Obama, President, United States of America - Engaging China on Biotechnology

Letter

By: Erik Paulsen, David Scott, Blake Farenthold, Dave Trott, Renee Ellmers, Kyrsten Sinema, Ann Wagner, Jackie Walorski, Mike Bost, Todd Young, Doug LaMalfa, Devin Nunes, French Hill, Andy Harris, Steve King, Blaine Luetkemeyer, Jim Renacci, Ryan Zinke, Raúl Labrador, John Moolenaar, Terri Sewell, Dan Donovan, Jr., Jim Sensenbrenner, Jr., Reid Ribble, Steve Pearce, Marlin Stutzman, Randy Weber, Sr., Julia Brownley, John Shimkus, Luke Messer, Phil Roe, Pat Tiberi, Scott Tipton, Tom Reed II, Dave Reichert, Mark Meadows, Trent Franks, Kevin Yoder, Dan Kildee, Sean Duffy, Cathy McMorris Rodgers, Dave Loebsack, Kevin Cramer, Mac Thornberry, John Fleming, Jr., Tom Graves, Jr., Richard Hudson, Jr., Sam Graves, Tom Emmer, Ken Buck, Bill Johnson, Collin Peterson, David Young, Bob Latta, Mike Conaway, GT Thompson, Jr., Ron Kind, Tom Cole, Mike Turner, Randy Neugebauer, Jason Smith, Susan Brooks, Bob Goodlatte, Bill Foster, Stephen Fincher, Scott Perry, Jeff Fortenberry, Todd Rokita, Steve Stivers, Rob Bishop, Vicky Hartzler, David Rouzer, Paul Gosar, Sanford Bishop, Jr., Bob Gibbs, Ann Kirkpatrick, Kurt Schrader, Mike Pompeo, Chris Collins, Kristi Noem, Tim Walz, Larry Bucshon, Scott DesJarlais, Lynn Jenkins, Tom Rooney, Tom Marino, Ted Yoho, Mike Kelly, Jr., Pat Meehan, Brad Wenstrup, Cheri Bustos, Bradley Byrne, Martha McSally, Fred Upton, Mike Simpson, Rod Blum, Filemon Vela, Jr., Frank Lucas, George Holding, Peter Roskam, Billy Long, Rick Crawford, Suzan DelBene, Adrian Smith, Robert Aderholt, Rodney Davis, Dan Benishek, Ralph Abraham, Jim Costa, Dan Newhouse
Date: Oct. 28, 2016
Location: Washington, DC

Dear Mr. President,

We appreciate your administration's continued efforts to engage the People's Republic of China -- a vital U.S. trading partner -- on the topic of agricultural innovation and trade. Though some progress has been made, we request that agricultural biotechnology remain a top priority for the United States as we engage the Chinese through a series of meetings this fall, including the Joint Commission on Commerce and Trade (JCCT) in November.

Over the past three years, your administration has successfully secured commitments from Chinese officials to pursue a more normalized trading relationship and improve the approval process for products of agricultural biotechnology. Despite this very promising engagement, we continue to see a disconnect between Chinese commitments and action. For instance, in February, three out of 11 biotech products were approved, but China has issued no approvals since that time. The backlog continues to grow. Currently there are a total of 25 biotech products in the regulatory queue in China, including eight in the final stage. Four of these products have been under review since mid-2011.

We recognize that regulatory reform in China is complex and will require time. However, we are alarmed that recent amendments to China's biotech regulatory regime effectively provide less clarity and specificity around the approval process, rather than more transparency and accountability. This development appears to run counter to commitments made to the United States, and raises serious questions regarding China's intention to follow through on the spirit of the agreements made in September 2015 and June 2016.

China continues to be a very significant trading partner for U.S. agriculture. In 2015 China purchased $20.3 billion worth of American agricultural products, roughly $10.8 billion, or 54%, of which were biotech-derived plant products. Paving a path forward through continued high-level engagement is essential to facilitate a more positive trade environment and relationship, including for products of agricultural biotechnology. The U.S. agricultural value chain is committed to working with the United States and Chinese governments to support these efforts. Delayed approvals that limit access to innovative products and encumber trade only serve to undermine the progress made to date and significantly dampens innovation and trade affecting both the U.S. and Chinese economies.

As your team engages their Chinese counterparts in preparation for the JCCT, we ask that you place added focus on transitioning China's commitments into positive action. Thank you again for your efforts on behalf of U.S. agriculture and trade.

Sincerely,


Source
arrow_upward